Canada’s Drug Agency | Drugs, Health Technologies and Systems.

efgartigimod alfa

Details

Generic Name:
efgartigimod alfa
Project Status:
Pending
Therapeutic Area:
Chronic inflammatory demyelinating polyneuropathy
Manufacturer:
argenx Canada
Call for patient/clinician input open:
Brand Name:
Vyvgart
Project Line:
Reimbursement Review
Project Number:
SR0894-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​Vyvgart (efgartigimod alfa injection) is indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Vyvgart (efgartigimod alfa injection) is indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : April 22, 2025